Quantum Immunologics (QI) has begun a US Food and Drug Association-authorised trial to test the safety and efficacy of the company's new dendritic cell therapy immunotherapy treatment.
The trial will be conducted on 27 stage IV breast cancer patients who have failed conventional therapy.
Mentor Capital, which recently acquired 20% in QI, CEO Chet Billingsley said that the company will reveal buying opportunities soon now that the company has reached the clinical stage.
Dendritic cell therapy employs oncofoetal antigen (OFA) to recruit the patient's own immune system to target and attack the cancer cells.
Each patient will receive three monthly injections of their own dendritic cells that have been sensitised to OFA.